Abstract:Antiapoptotic members of B-cell leukemia/lymphoma-2 (BCL-2) family proteins are one of the overexpressed proteins in cancer cells that are oncogenic targets. As such, targeting of BCL-2 family proteins raises hopes for new therapeutic discoveries. Thus, we used multistep screening and filtering approaches that combine structure and ligand-based drug design to identify new, effective BCL-2 inhibitors from a small molecule database (Specs SC), which includes more than 210,000 compounds. This database is first filtered based on binary "cancer-QSAR" model constructed with 886 training and 167 test set compounds and common 26 toxicity quantitative structure-activity relationships (QSAR) models. Predicted non-toxic compounds are considered for target-driven studies. Here, we applied two different approaches to filter and select hit compounds for further in vitro biological assays and human cell line experiments. In the first approach, a molecular docking and filtering approach is used to rank compounds based on their docking scores and only a few top-ranked molecules are selected for further long (100-ns) molecular dynamics (MD) simulations and in vitro tests. While docking algorithms are promising in predicting binding poses, they can be less prone to precisely predict ranking of compounds leading to decrease in the success rate of in silico studies. Hence, in the second approach, top-docking poses of each compound filtered through QSAR studies are subjected to initially short (1 ns) MD simulations and their binding energies are calculated via molecular mechanics generalized Born surface area (MM/GBSA) method. Then, the compounds are ranked based on their average MM/GBSA energy values to select hit molecules for further long MD simulations and in vitro studies. Additionally, we have applied text-mining approaches to identify molecules that contain "indol" phrase as many of the approved drugs contain indole and indol derivatives. Around 2700 compounds are filtered based on "cancer-QSAR" model and are then docked into BCL-2. Short MD simulations are performed for the top-docking poses for each compound in complex with BCL-2. The complexes are again ranked based on their MM/GBSA values to select hit molecules for further long MD simulations and in vitro studies. In total, seven molecules are subjected to biological activity tests in various human cancer cell lines as well as Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) assay. Inhibitory concentrations are evaluated, and biological activities and apoptotic potentials are assessed by cell culture studies. Four molecules are found to be limiting the proliferation capacity of cancer cells while increasing the apoptotic cell fractions.

Selection of Effective Bcl-2 Antisense Oligodeoxynucleotides with Computer Software and Experimental Assay

Effect of Bcl-2 Antisense Oligodeoxynucleotides on Drug Sensitivity of Leukemic Cells

Design of Bcl-2 antisense oligodeoxynucleotide and study of its induction apoptosis in K562 cells

[Design of Antisense Oligodeoxynucleotide Targeting at Bcl-2 Mrna and Observation on Its Effect on the Sensitivity of Leukemia Cells to Arabinosyl Cytosine].

Effect of two new bcl-2 antisenses on drug-sensitivity of cells fromn leukemia patients

Effect of Bcl-2 Antisense Oligonucleotide Targeting Different Region of Bcl-2 Mrna on Drug-Sensitivity of Leukemia Cells

Bcl-2 Antisense Oligodeoxynucleotide Enhances Araninosyl Cytosine-Induced Apoptosis of Primary Leukemia Cells

Effect of antisense oligodeoxynucleotide targeted against bcl-2 gene on growth and apoptotic susceptibility of leukemia cells

Effect of BcL-2 Antisense Drug with Different Structure on the Biological Function of K562 Cells

Antisense Oligodeoxynucleotides Inhibit Bcl-2 Expression and Induce Apoptosis in Acute Lymphocytic Leukemia Cells

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

Optimization of antisense drug design against conservative local motif in simulant secondary structures of HER-2 mRNA and QSAR analysis.

Study on antisense oligoncleotides as inhibitor of human acute promyelocytic leukemia proliferation and protein expression

Bcl-2 antisense oligodeoxynucleotide increases the sensitivity of HL60 and K562 cells to daunorubicin

Discovery of Small-Molecule Inhibitors of Bcl-2 Through Structure-Based Computer Screening.

Integrating Ligand and Target-Driven Based Virtual Screening Approaches With in vitro Human Cell Line Models and Time-Resolved Fluorescence Resonance Energy Transfer Assay to Identify Novel Hit Compounds Against BCL-2

The Effect of the Target of Bcl-2 Antisense Phosphorothioate Oligodexynucleotides Combined with Chemotherapy on HL60 Cell Line and the Primary Leukemia Cells

Antisense Drug Targeting with VEGF Mrna Designed by Computer Aid and Inhibitory Effects on K562 Cell Line in Vitro

The effect of antisense bcl-2 oligonucleotides on bcl-2 protein expression and apoptosis in human colon cancer cells

Rational design and rapid screening of antisense oligonucleotides for prokaryotic gene modulation

Antisense Oligonucleotides: Promise and Reality